Skip to main content
. 2013 Nov 5;5(4):400–409. doi: 10.1111/jdi.12160

Figure 2.

image

(a) Serial changes in glycated hemoglobin (HbA1c) during the 24 weeks with vildagliptin or vildagliptin + nateglinide. (b) Mean changes in HbA1c at the end‐point in the two treatment groups. #P < 0.001, the combination group versus the switching group.